C
Capacity Bio
Targeting fundamental biology for radical therapeutic benefits
About Capacity Bio
Capacity Bio is a private biotechnology company headquartered in Los Angeles, California. The company is developing a first-in-class therapeutic platform focused on mitophagy, the process of clearing and recycling damaged mitochondria. In addition to its therapeutic platform, the company is also creating an advanced analytical toolkit to characterize mitochondria.
The company's primary objective is to restore mitochondrial quality control in various diseases. By targeting mitochondrial biology, Capacity Bio aims to develop therapeutic breakthroughs. The company was co-founded by Amy Wang and Kathy Rodgers, among others. Capacity Bio has secured $35 million in a funding round from three investors.
As a therapeutics company, Capacity Bio operates within the biotechnology and healthcare sectors. Its business model is centered around the research and development of small molecules, peptides, and nanoparticles. The company's potential clients include larger pharmaceutical and biotechnology companies that may license or acquire its developed therapies.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Los Angeles, United States
- Employees
- 8
- Open positions
- None listed
- Dealroom signal
- 61.2/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Mar 2023 | $35M | $140M | Insight Partners · RA Capital Management | ↗ |
| SEED✓Equity / VC | Jan 2022 | — | — | Remiges Ventures | ↗ |
Growth signals
Latest recorded traffic for Capacity Bio is 310 monthly website visits, down 34% over the last three months. Capacity Bio's team declined 20% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Remiges Ventures
Series A2 investors entered at this stage
Other known investors3 additional known investors
University of California, Los Angeles
AN Venture Partners
RDiscovery
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Capacity Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Capacity Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.